Novo Nordisk Faces Mounting Pressure Amid Regulatory Milestone and Generic Threats

Novo Nordisk gains EU approval for higher-dose Wegovy but faces imminent generic competition from Dr. Reddy's, while advancing its pipeline and share buyback.

Novo Nordisk finds itself navigating a complex landscape of opportunity and challenge. While the pharmaceutical giant recently secured a significant regulatory win in Europe, this achievement coincides with intensifying competitive pressures that threaten its lucrative obesity drug franchise.

Share Buyback Program Progresses as Forecast

The company's substantial share repurchase initiative, announced in February, is proceeding according to plan. This program, valued at 15 billion Danish kroner, has seen an initial tranche executed. By February 6, Novo Nordisk had repurchased 750,000 of its B shares at an average price of 296.40 kroner per share, amounting to a total transaction value of 222.3 million kroner. The current phase of this buyback strategy is targeting acquisitions worth up to 3.8 billion kroner, with completion expected by early May.

European Approval for Higher-Dose Wegovy Secured

In a key development, the European Commission granted authorization on February 17 for a higher 7.2-milligram dosage of Novo Nordisk's weight-loss medication, Wegovy. This approval allows physicians within the European Union to prescribe the treatment as three combined 2.4-mg injections per week. Clinical data underpinning this decision comes from a 72-week study involving 1,407 adult participants without diabetes. The results demonstrated that the elevated dose yielded an average weight reduction of 20.7%, a marked improvement over the 17.5% loss associated with the standard dosage.

Furthermore, the Danish firm has submitted an additional application for a pre-filled 7.2 mg pen device, which could become available later this year.

Generic Competition Looms, Threatening Profitability

The timing of this regulatory success is critical, as the market prepares for a wave of lower-cost alternatives. Indian manufacturer Dr. Reddy's Laboratories announced on the very same day as the EU approval that it plans to introduce a generic version of Wegovy, priced 50 to 60 percent below the branded product. This move is facilitated by the impending expiration of the semaglutid patent in March 2026. Dr. Reddy's has already obtained approval from Indian drug authorities for a generic version of Ozempic, another Novo Nordisk product containing semaglutide, and is awaiting a green light for its Wegovy equivalent.

Pipeline Advancement Offers a Glimmer of Future Growth

Concurrently, Novo Nordisk is advancing its research pipeline to fortify its long-term position. Also on February 17, the company initiated a Phase 2 clinical trial for a novel compound, UBT251, targeting overweight and obesity conditions. This study is designed to evaluate the safety, tolerability, and efficacy of various dosages against a placebo. Participant recruitment for this trial is currently underway.

Despite these strategic efforts, the company's shares remain under pressure. In February, management issued a forecast projecting a sales decline of five to thirteen percent for the year 2026. This anticipated downturn is attributed to a combination of pricing pressures in the crucial U.S. market, patent expirations, and a more competitive landscape. While the new higher-dose Wegovy formulation may provide some counterbalance, the imminent arrival of generic competitors is expected to significantly squeeze profit margins.